A Phase I Study of Nilotinib in Combination with Dabrafenib and Trametinib or Encorafenib and Binimetinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK Inhibition

Disease Sites:

Melanoma, Phase I

Staging:

Phase I

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

AMN107, Binimetinib, Dabrafenib, Encorafenib, Nilotinib, Trametinib

Principal Investigator(s):

Johnson, Douglas

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

12-07-2023

Trial Type:

Treatment

Protocol ID:

VICCMELP2274

National Clinical Trial ID:

NCT04903119

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available